Covered recipient · General Payments record
PHILIP EDWARD LAMMERS
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$65,938.69
193 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,545.25 | 18 |
| Consulting Fee | $17,740.00 | 11 |
| Food and Beverage | $3,852.57 | 156 |
| Travel and Lodging | $2,800.87 | 8 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PHILIP EDWARD LAMMERS
NPI 1780802330 · CMS profile ID 80658
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
BARTLETT, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1780802330?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PHILIP EDWARD LAMMERS, NPI 1780802330, CMS profile ID 80658. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780802330?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). PHILIP EDWARD LAMMERS, NPI 1780802330, CMS profile ID 80658. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780802330?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- PHILIP EDWARD LAMMERS, NPI 1780802330, CMS profile ID 80658, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1780802330?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
193 matching records · $65,938.69 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 193.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $4.70 | 05/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206672819 | CMS |
| Daiichi Sankyo Inc. | $29.79 | 05/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197063739 | CMS |
| ABBVIE INC. | $22.53 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202261854 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.61 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184800363 | CMS |
| Iovance Biotherapeutics, Inc. | $11.75 | 05/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251401500 | CMS |
| Incyte Corporation | $21.67 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225979145 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.48 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184800361 | CMS |
| Gilead Sciences, Inc. | $28.82 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234445967 | CMS |
| PFIZER INC. | $17.83 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231338755 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $21.53 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225617279 | CMS |
| Daiichi Sankyo Inc. | $21.04 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197065473 | CMS |
| AstraZeneca Pharmaceuticals LP | $7,380.00 | 05/05/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206879284 | CMS |
| Iovance Biotherapeutics, Inc. | $48.59 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251396229 | CMS |
| Janssen Biotech, Inc. | $23.08 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174913830 | CMS |
| AstraZeneca Pharmaceuticals LP | $118.82 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206293118 | CMS |
| AstraZeneca Pharmaceuticals LP | $497.53 | 04/29/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206417368 | CMS |
| Daiichi Sankyo Inc. | $25.45 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197065515 | CMS |
| Novartis Pharmaceuticals Corporation | $19.23 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200698819 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,920.00 | 04/25/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206392594 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,280.00 | 04/25/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207311614 | CMS |
| Gilead Sciences, Inc. | $28.00 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234451382 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $17.13 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251747713 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206564649 | CMS |
| AstraZeneca Pharmaceuticals LP | $634.63 | 04/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206823194 | CMS |
| Iovance Biotherapeutics, Inc. | $12.79 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251396227 | CMS |
| E.R. Squibb & Sons, L.L.C. | $11.91 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184800347 | CMS |
| PFIZER INC. | $21.47 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228802179 | CMS |
| AstraZeneca Pharmaceuticals LP | $123.95 | 04/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206960846 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.61 | 04/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207315626 | CMS |
| Eisai Inc. | $14.39 | 04/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244505288 | CMS |
| PFIZER INC. | $20.54 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228814287 | CMS |
| Gilead Sciences, Inc. | $27.74 | 04/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234453421 | CMS |
| AstraZeneca Pharmaceuticals LP | $250.00 | 04/15/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206626296 | CMS |
| SpringWorks Therapeutics, Inc. | $40.92 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232164303 | CMS |
| Genentech, Inc. | $14.23 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211567618 | CMS |
| Lilly USA, LLC | $21.63 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186780553 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $13.59 | 04/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251046268 | CMS |
| Celgene Corporation | $25.31 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184800349 | CMS |
| Tempus AI, Inc | $14.38 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250347998 | CMS |
| Eisai Inc. | $16.80 | 04/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244505286 | CMS |
| Gilead Sciences, Inc. | $19.44 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234534209 | CMS |
| Merck Sharp & Dohme LLC | $25.29 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238385632 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.86 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206301226 | CMS |
| Amgen Inc. | $2,920.50 | 03/25/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226873241 | CMS |
| Amgen Inc. | $271.04 | 03/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226874452 | CMS |
| Amgen Inc. | $2,920.50 | 03/25/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226899974 | CMS |
| Gilead Sciences, Inc. | $27.02 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234458330 | CMS |
| PFIZER INC. | $13.24 | 03/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231570909 | CMS |
| Karyopharm Therapeutics Inc. | $20.09 | 03/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246650427 | CMS |
| Tempus AI, Inc | $19.02 | 03/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250347996 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,334.64 | 1 |
| PY2025 | Principal investigator | $690,641.69 | 59 |
| PY2024 | Principal investigator | $1,125,319.16 | 50 |
| PY2023 | Principal investigator | $313,910.92 | 49 |
| PY2022 | Recipient | $2,376.00 | 1 |
| PY2022 | Principal investigator | $176,173.23 | 32 |
| PY2021 | Principal investigator | $62,871.40 | 11 |
| PY2020 | Principal investigator | $111,504.07 | 8 |
| PY2019 | Principal investigator | $6,648.00 | 5 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
60 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $68,062.68 | 12/31/2025 | Non-covered Recipient Entity Baptist Cancer Center | A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received | No dispute reported | 06/30/2026 | 1232924418 |
| Principal investigator 1 | Janssen Research & Development, LLC | $561.00 | 12/25/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After Osimertinib Failure | No dispute reported | 06/30/2026 | 1175369778 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $10,653.36 | 12/24/2025 | Non-covered Recipient Entity Baptist Clinical Research Institute Inc | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199912129 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746256 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $998.00 | 11/06/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 117145 | No dispute reported | 06/30/2026 | 1252498695 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746254 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,724.00 | 10/23/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233737175 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,250.00 | 10/23/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233737177 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $117.00 | 10/23/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233737179 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 10/23/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233737181 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746252 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 09/29/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175369868 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $509.10 | 09/24/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746236 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 09/24/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $539.46 | 09/24/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746240 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 09/24/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746242 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $244.28 | 09/24/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746244 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.68 | 09/24/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746246 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.00 | 09/24/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746248 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.66 | 09/24/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746250 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 09/12/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746234 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $500.00 | 09/09/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 117145 | No dispute reported | 06/30/2026 | 1252497931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity Baptist Trinity Home Care And Hospice-Memphis | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220746232 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $282.40 | 08/14/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 101623 | No dispute reported | 06/30/2026 | 1252497699 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,920.00 | 08/11/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175369861 |
| Principal investigator 1 | AstraZeneca UK Limited | $12,070.00 | 07/23/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | a multicentre,open label study assessing ophthalmic safety of camizestrant in ER,HER2 early breast cancer patients either initiating adjuvant endocrine based therapy cambria 2 or having been treated with standard adjuvant endocrine based therapy for at least 2 years cambria 1 | No dispute reported | 06/30/2026 | 1185541742 |
| Principal investigator 1 | Genentech, Inc. | $2,034.90 | 07/18/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INST INC | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211576958 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,790.00 | 07/10/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175369873 |
| Principal investigator 1 | Genentech, Inc. | $13,500.00 | 07/02/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INST INC | Early Stage to Locally Advanced Non Small Cell Lung Cancer platform stage 3 unresectable | No dispute reported | 06/30/2026 | 1211576940 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,368.42 | 06/24/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 117145 | No dispute reported | 06/30/2026 | 1252496049 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,996.00 | 06/24/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 117145 | No dispute reported | 06/30/2026 | 1252496279 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $13,234.32 | 06/24/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 117145 | No dispute reported | 06/30/2026 | 1252496281 |
| Principal investigator 1 | Amgen Inc. | $158,554.51 | 06/17/2025 | Non-covered Recipient Entity BAPTIST CANCER CENTER MEMPHIS THORACIC | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | No dispute reported | 06/30/2026 | 1246639517 |
| Principal investigator 1 | Genentech, Inc. | $3,500.00 | 06/13/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INST INC | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211576946 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,944.00 | 06/09/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175369829 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,330.04 | 06/04/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) | No dispute reported | 06/30/2026 | 1185541730 |
| Principal investigator 1 | Amgen Inc. | $174,207.17 | 05/22/2025 | Non-covered Recipient Entity BAPTIST CANCER CENTER MEMPHIS THORACIC | A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) | No dispute reported | 06/30/2026 | 1246639519 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,682.80 | 05/13/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 117145 | No dispute reported | 06/30/2026 | 1252496275 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $66.00 | 05/13/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 117145 | No dispute reported | 06/30/2026 | 1252496277 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $3,090.40 | 04/24/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 101623 | No dispute reported | 06/30/2026 | 1252495883 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,500.00 | 04/16/2025 | Non-covered Recipient Entity Bapt Clinic Rsrch Inst | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175273129 |
| Principal investigator 1 | Genentech, Inc. | $7,947.90 | 04/04/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INST INC | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211576950 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $250.00 | 04/02/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | No dispute reported | 06/30/2026 | 1185541736 |
| Principal investigator 1 | Genentech, Inc. | $8,597.00 | 04/01/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INST INC | NAUTIKA1 previously LCMC4 | No dispute reported | 06/30/2026 | 1211576954 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,972.00 | 03/31/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175369811 |
| Principal investigator 1 | AstraZeneca UK Limited | $27,324.90 | 03/19/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | No dispute reported | 06/30/2026 | 1185541740 |
| Principal investigator 1 | AstraZeneca UK Limited | $10,156.04 | 03/10/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) | No dispute reported | 06/30/2026 | 1185541738 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,972.00 | 02/28/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175369822 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,000.00 | 02/24/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175369882 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,206.66 | 02/19/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185541734 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $693.90 | 02/18/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 117145 | No dispute reported | 06/30/2026 | 1252496315 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,955.20 | 02/11/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 101623 | No dispute reported | 06/30/2026 | 1252496337 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,916.00 | 02/03/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175369771 |
| Recipient | Amgen Inc. | $2,334.64 | 02/01/2025 | Covered Recipient Physician | Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1246637188 |
| Principal investigator 1 | Amgen Inc. | $18,954.40 | 01/29/2025 | Non-covered Recipient Entity BAPTIST CANCER CENTER MEMPHIS THORACIC | A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy | No dispute reported | 06/30/2026 | 1246639523 |
| Principal investigator 1 | Amgen Inc. | $29,340.59 | 01/27/2025 | Non-covered Recipient Entity BAPTIST CANCER CENTER MEMPHIS THORACIC | A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) | No dispute reported | 06/30/2026 | 1246639521 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,050.00 | 01/24/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole | No dispute reported | 06/30/2026 | 1185541732 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $98.00 | 01/17/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE INC | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233737173 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $500.00 | 01/02/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 117145 | No dispute reported | 06/30/2026 | 1252496547 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $600.00 | 01/02/2025 | Non-covered Recipient Entity BAPTIST CLINICAL RESEARCH INSTITUTE | 117145 | No dispute reported | 06/30/2026 | 1252496549 |